Outcome and Morphofunctional Changes on Cardiac Magnetic Resonance in Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Acute myocarditis following mRNA COVID-19 vaccination. Intervention: mRNA COVID-19 vaccination. Primary outcome: Risk of adverse events after discharge and the extent of residual myocardial dysfunction and scar formation.

Enrico Ammirati; Laura Lupi; Matteo Palazzini; Michele Ciabatti; Valentina A. Rossi; Piero Gentile; Aitor Uribarri; Chiara Vecchio; Daniele Nassiacos; Alberto Cereda; Cristina Conca; Gabriele Tumminello; Nicolas Piriou; Coline Lelarge; Patrizia Pedrotti; Miriam Stucchi; Giovanni Peretto; Michele Galasso; Florent Huang; Umberto Ianni; Antonio Procopio; Gianluigi Saponara; Paolo Cimaglia; Daniela Tomasoni; Francesco Moroni; Annalisa Turco; Simone Sala; Giuseppe Di Tano; Entela Bollano; Claudio Moro; Antonio Abbate; Roberta Della Bona; Italo Porto; Stefano Carugo; Jeness Campodonico; Gianluca Pontone; Aurelia Grosu; Leonardo Bolognese; Jorge Salamanca; Pablo Díez‐Villanueva; Krzysztof Ozierański; Agata Tymińska; Loren Sardo Infirri; Daniel I. Bromage; Antonio Cannatà; Kimberly N. Hong; Marianna Adamo; G Quattrocchi; Alberto Foà; Luciano Potena; Andrea Garascia; Cristina Giannattasio; Eric Adler; Gianfranco Sinagra; Frank Ruschitzka; Paolo G. Camici; Marco Metra; Maurizio Pieroni

doi:10.1161/circheartfailure.122.010315

May 15, 2023Circulation Heart FailureOpen Access

Outcome and Morphofunctional Changes on Cardiac Magnetic Resonance in Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Although the short-term prognosis of mRNA COVID-19 vaccine-related acute myocarditis is reported to be favorable, scarce information is available regarding its midterm prognosis, post-discharge adverse event risk, and residual myocardial dysfunction or scar formation.

What is the risk of adverse events and the extent of residual myocardial dysfunction and scar formation on CMRI during midterm follow-up in patients with acute myocarditis following mRNA COVID-19 vaccination?

Study Design

Type

Observational

Structured PICO

What is the risk of adverse events and the extent of residual myocardial dysfunction and scar formation on CMRI during midterm follow-up in patients with acute myocarditis following mRNA COVID-19 vaccination?

P

Population

A series of 7 to 9 patients with acute myocarditis following mRNA COVID-19 vaccination who underwent baseline and follow-up cardiac magnetic resonance imaging.

E

Exposure

Baseline and follow-up cardiac magnetic resonance imaging (CMRI)

O

Outcome

Risk of adverse events after discharge and the extent of residual myocardial dysfunction and scar formationsurrogate

This case series aims to evaluate the midterm prognosis, including adverse events and CMRI morphofunctional changes, in patients with acute myocarditis following mRNA COVID-19 vaccination.

Implication

Limited series precludes practice change; leaves open midterm prognosis of mRNA vaccine myocarditis.

Abstract

Messenger RNA (mRNA) COVID-19 vaccination has been associated with a higher-than expected occurrence of acute myocarditis, although the benefits of the vaccine greatly outweigh the risk of myocarditis. Even if the short-term prognosis of mRNA vaccine–related myocarditis has been reported to be favorable, scarce information is available on midterm prognosis. The current series included 7 to 9 patients with baseline and follow-up cardiac magnetic resonance imaging (CMRI). Questions on acute myocarditis following mRNA COVID-19 vaccination addressed by this study are the risk of adverse events after discharge and the extent of residual myocardial dysfunction and scar formation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ammirati et al. (2023) conducted an observational in Acute myocarditis following mRNA COVID-19 vaccination. mRNA COVID-19 vaccination was evaluated on Risk of adverse events after discharge and the extent of residual myocardial dysfunction and scar formation.

synapsesocial.com/papers/6a6d62f226a7f98052db7347 https://doi.org/10.1161/circheartfailure.122.010315